We designed ACC by engineering genetic fusion of a cytokine (such as the IL-2 mimetic Neo2/15) on the C-terminus of the constant heavy chain of a tumor-specific anti-Tyrp1 antibody TA99 (Figure 1A) (22). This evidence concerns the gene IL2 and neoplasm.